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Abstract: Facioscapulohumeral muscular dystrophy (FSHD) is believed to be caused by 
aberrant expression of double homeobox 4 (DUX4) due to epigenetic changes of the  
D4Z4 region at chromosome 4q35. Detecting DUX4 is challenging due to its stochastic 
expression pattern and low transcription level. In this study, we examined different cDNA 
synthesis strategies and the sensitivity for DUX4 detection. In addition, we investigated the 
effects of dexamethasone and knockout serum replacement (KOSR) on DUX4 expression 
in culture. Our data showed that DUX4 was consistently detected in cDNA samples 
synthesized using Superscript III. The sensitivity of DUX4 detection was higher in the 
samples synthesized using oligo(dT) primers compared to random hexamers. Adding 
dexamethasone to the culture media significantly suppressed DUX4 expression in 
immortalized (1.3 fold, p < 0.01) and primary (4.7 fold, p < 0.01) FSHD myoblasts, 
respectively. Culture medium with KOSR increased DUX4 expression and the response is 
concentration dependent. The findings suggest that detection strategies and culture 
conditions should be carefully considered when studying DUX4 in cultured cells. 
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Facioscapulohumeral muscular dystrophy (FSHD) is a dominant muscular dystrophy, with a prevalence 
of 1:20,000, and the third most common type of muscular dystrophy [1]. The disease is characterized 
by a progressive weakness and atrophy of the facial, scapular, and humeral muscles followed by 
weakness of muscles of the lower extremities [2]. While clinically indistinguishable, FSHD is  
sub-classified into FSHD1 and FSHD2 depending on the genetic causes. FSHD1 is genetically linked 
to contractions of the D4Z4 repeat array at chromosome 4q35 and affects approximately 95% of the 
patients. In FSHD1, the D4Z4 array is contracted from 11–150 repeat units in unaffected individuals to 
1–10 repeat units in the patients [3–5]. Each D4Z4 repeat contains a double homeobox protein 4 
(DUX4) which is cytotoxic when ectopically expressed, as shown by both in vivo and ex vivo  
studies [6–10]. Previous studies showed that a combination of two genomic features is required to 
cause FSHD. First, the contraction of the D4Z4 repeats, which leads to DNA hypomethylation of the 
D4Z4 region and allows DUX4 mRNA to be transcribed [11]. Second, an intact polyadenylation signal 
in the region distal to the last repeat of D4Z4, which allows the DUX4 transcripts from the last D4Z4 
repeat to be polyadenylated, thus stable for protein translation. The combination leads to the aberrant 
expression of DUX4 and downstream molecular changes involved in FSHD [12–15]. This disease 
model was further supported by the identification of mutations in a gene named structural maintenance 
of chromosomes flexible hinge domain containing 1 (SMCHD1) in FSHD2, which encodes a 
chromatin modifier of D4Z4. Haploinsufficiency of the SMCHD1 coupled with the FSHD permissive 
allele was shown to be causative of the FSHD2 [16]. 
DUX4 expression in primary myoblasts from patients with FSHD has been showed to be stochastic. 
Previous studies report 1 in 1000 nuclei is DUX4 positive in proliferating FSHD myoblasts; and 1 in 
200 nuclei during myoblast differentiating [17,18]. Due to the extremely low expression level of  
the DUX4, detection of DUX4 transcripts has been challenging. Several different DUX4 detection 
strategies have been reported, using different reverse transcriptases (RT) and primers [e.g. oligo(dT), 
random hexamers] for cDNA synthesis [13,19–21]. In some studies, DUX4 expression was amplified 
using nested PCR [17,22]. These strategies have not been compared side-by-side, and often fail to 
detect endogenously produced DUX4 in a different laboratory. 
While DUX4 expresses in very few number of cells during proliferation, the expression level of 
DUX4 increases during differentiation. This observation suggests that the expression of DUX4 can  
be modulated by the physiological state of the cells and culture environment. Dexamethasone is  
a glucocorticoid which stimulates myoblasts proliferation and is often added in culture to promote cell 
growth [23]. KOSR is a serum replacement often used for culturing stem cells and was suggested to 
protect cells via its antioxidative property [24]. A recent study also reported higher DUX4 expression 
in differentiating FSHD myoblasts cultured in medium with 20% KOSR [19]. In this study, we 
cultured immortalized FSHD myoblasts in growth medium with or without dexamethasone and KOSR, 
respectively, to determine the effects of culture conditions on DUX4 expression. In addition, effects of 
different concentrations of KOSR on DUX4 expression in differentiating cells were determined. The 
purpose of this study is to identify a sensitive detection strategy for DUX4 transcripts and to determine 
how culture conditions affect DUX4 expression in cell culture. 
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2. Results and Discussion 
Detecting DXU4 expression in FSHD myoblasts has been very challenging, primarily due the 
stochastic expression and cytotoxic nature of DUX4, which lead to an extremely low number of cells 
expressing DUX4 in culture. Different sample preparation and RT conditions have been used and 
reported previously, which are listed in Supplementary Table S1. In order to identify the most effective 
method to detect DUX4 expression in FSHD myoblasts, we tested two most commonly used reverse 
transcriptases, Superscript II and Superscript III, and two types of primers, oligo(dT) and random 
hexamers. Our result showed that DUX4 expression was easily detected in FSHD myoblasts when the 
cDNA was synthesized using Superscript III. Whereas DUX4 expression was not detected in cDNA 
samples synthesized using Superscript II (Figure 1). In addition to the reverse transcriptases, we 
examined the effects of primers used for cDNA synthesis. Our data showed that higher DUX4 
expression (1.7 fold, p < 0.01) was detected in cDNA samples synthesized using oligo(dT) primers 






Figure 1. DUX4 was detected in cDNA synthesized using Superscript III but not 
Superscript II. Four independent cultures of immortalized FSHD myoblasts in growth 
medium with 15% KOSR (without dexamethasone) were examined for each group. cDNA 
samples were synthesized using either Superscript II (left panel) or Superscript III (right 
panel). Oligo(dT) primers were used for this experiment. 
2.1. KOSR and Dexamethasone in Culture Media Affect DUX4 Expression in FSHD Myoblasts 
To determine the effects of KOSR and dexamethasone on DUX4 expression in culture, we cultured 
FSHD immortalized myoblasts in regular growth medium containing 15% FBS with dexamethasone, 
15% FBS medium without dexamethasone, 15% KOSR with dexamethasone and 15% KOSR medium 
without dexamethasone. Our data showed that DUX4 expression was not detected in FSHD myoblasts 
cultured in growth medium containing FBS, either with or without dexamethasone. DUX4 expression 
was detected in FSHD myoblasts cultured in growth medium with KOSR (Figure 2). DUX4 expression 
in FSHD myoblasts cultured in KOSR medium without dexamethasone was 1.3 fold higher (p < 0.01) 
than cells cultured in KOSR medium with dexamethasone (Figure 2). 





DEX            +         ‐ +          ‐ +          ‐ +           ‐  
Figure 2. Higher sensitivity of DUX4 detection in cDNA samples synthesized using 
oligo(dT) primers compared to those synthesized using random hexamers. In addition, 
higher expression of DUX4 was detected in cells cultured in growth medium with 15% 
KOSR instead of 15% FBS. Adding dexamethasone reduced DUX4 expression. DEX, 
dexamethasone; FBS, fetal bovine serum; KOSR, knockout serum replacement;  
“**”: p < 0.01. 
To increase biological sample size, we further validated the effects of dexamethasone on DUX4 
expression using 5 pairs of primary myoblasts. Primary FSHD myoblasts were cultured in growth 
medium with 15% KSOR (with or without dexamethasone) for 3 days, respectively. We observed  
a significant reduction in DUX4 expression (4.7 fold, p < 0.01) in dexamethasone-treated FSHD 
myoblasts in comparison to untreated FSHD myoblasts (Figure 3). 
**
CON                                FSHD                              FSHD  
Figure 3. Dexamethasone reduced DUX4 expression in primary FSHD myoblasts. Control 
(n = 5) and FSHD (n = 5) myoblasts were cultured in growth medium with 15% KSOR, 
either with or without dexamethasone, respectively, for 3 days. DEX, dexamethasone; CON, 
control; “**”: p < 0.01. 
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KOSR containing differentiation medium has been reported to facilitate differentiation of FSHD 
myoblasts and increases DUX4 expression in myotubes [19]. Therefore, we examined expression level 
of two myogenic factors, myogenic differentiation antigen 1 (MYOD) and myogenin (MYOG), in the 
FSHD myoblasts cultured in media containing either FBS or KOSR, with or without dexamethasone, 
respectively. Expression of both MYOD and MYOG increased in myoblasts cultured in growth 
medium containing KOSR (Figure 4). Adding dexamethasone increased MYOD expression in the 
myoblasts cultured in medium containing FBS as well as in medium containing KOSR (Figure 4A). 
Adding dexamethasone did not significantly affect MYOG expression in myoblasts cultured in growth 
medium containing KOSR (Figure 4B). However, MYOG was decreased by dexamethasone in 
myoblasts cultured in growth medium containing FBS (Figure 4B). 
 
Figure 4. KOSR and dexamethasone affect MYOD and MYOG expressions in immortalized 
FSHD myoblasts. Expression level of MYOD (A) and MYOG (B) were affected differently 
by KOSR and dexamethasone. DEX, dexamethasone; FBS, fetal bovine serum; KOSR, 
knockout serum replacement; “*”: p < 0.05; “**”: p < 0.01. 
2.2. Concentration-Dependent Increase of DUX4 in FSHD Myotubes Cultured in Differentiation 
Medium with KOSR 
Horse serum at 2% concentration is commonly used in differentiation media. To determine whether 
KOSR promote differentiation and DUX4 expression more than HS, we replaced 2% HS with 2% 
KOSR in differentiation media. In addition, we determined how different concentrations (2%, 10%, 
15% and 20%) of KOSR affected DUX4 expression in FSHD myotubes. 
Our results showed that DUX4 expression was not significantly higher in FSHD myotubes cultured 
in 2% KOSR, however it was increased in FSHD myotubes cultured in 10% KOSR (3.77 fold,  
p < 0.01), 15% KOSR (5.58 fold, p < 0.01), and 20% KOSR (2.87 fold, p < 0.01) compared to 2% HS 
(Figure 5). In addition, the expression was significantly different among the cultures with different 
concentrations of KOSR. DUX4 expression was the highest in myotubes cultured in differentiation 
medium with 15% KOSR (Figure 5). 











Figure 5. Concentration-dependent increase of DUX4 in differentiated FSHD myotubes in 
response to KOSR. Immortalized FSHD myoblasts were differentiated in media with 2% 
HS, 2% KOSR, 10% KOSR, 15% KOSR, and 20% KOSR, respectively. The mRNA 
expression of DUX4 were quantified using qRT-PCR. CON, control; * p < 0.05; ** p < 0.01.  
2.3. Discussion 
Ectopic expression of DUX4 in cells and animal models has been shown to induce cell apoptosis 
and is cytotoxic [6,9,10]. It is hypothesized that few DUX4-positive FSHD myoblasts are detected in 
culture because the expression of DUX4 is stochastic, and once the DUX4 is expressed in certain cells, 
the cells expressing DUX4 do not survive long. In this study, we examined different cDNA synthesis 
strategies to determine which strategy can most sensitively detect DUX4 expression in cultured FSHD 
myoblasts. In addition, we identified cell culture conditions that affected expression level of DUX4 in 
cell culture, including agents that increased and reduced DUX4 expression, respectively. The findings 
showed that, in addition to detecting DUX4, the expression of DUX4 can be significantly affected  
by the culture condition; therefore, the culture conditions need to be taken into consideration when 
planning an experiment using FSHD myoblasts. 
Several different DUX4 detection strategies have been reported previously, including different reverse 
transcriptases (RT) and primers [e.g., oligo(dT), random hexamers] for cDNA synthesis [13,20,21]. 
Our results showed that Superscript III is more sensitive than Superscript II for detecting DUX4. This 
is likely due to that Superscript III is more sensitive for detecting RNAs expressing at low levels. In  
a previous study Superscript III, but not Superscript II, was shown to be one of the 5 RT enzymes with 
the highest sensitivity in detecting low copy RNA among 11 RT enzymes tested [25]. In addition to  
the RT enzymes, our data showed that oligo(dT) priming increased detection sensitivity compared to 
random hexamers priming. A previous study suggested that a higher coverage of transcripts were 
synthesized when oligo(dT) primers were used. In this study, only two out of 8 genes were efficiently 
detected in cDNA synthesized by hexamers, while all genes were efficiently detected in cDNA 
synthesized by oligo(dT) [26]. In our study, both priming methods allowed DUX4 detection but with 
different sensitivities. This may be due to that cDNA samples generated with random hexamers tend to 
carry sequence-specific mismatch errors, which can potentially reduce priming efficiency during PCR [27]. 
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KOSR is an artificial serum replacement with a defined formula (Life Technologies, Frederick, MD, 
USA). It is often used for culturing stem cells and has been shown to have various cellular effects, 
including interfering with wnt-mediated cell differentiation, and protect stem cells from apoptosis via 
its anti-oxidative components [24,28]. Previous studies have reported that higher DUX4 expression is 
associated with increased myoblast differentiation [18,19]. In our study, myogenic factors, MYOD and 
MYOG were up-regulated in myoblasts cultured in growth medium with 15% KOSR (3 days in 
KOSR), which suggested that replacing 15% FBS with 15% KOSR in a typical growth medium might 
have initiated cell differentiation program. This finding suggested that the expression change of DUX4 
may be in response to cell differentiation. In addition, KOSR may not be used to replace FBS in 
growth media for maintaining FSHD myoblasts. Meanwhile, other known effects of KOSR may 
explain the higher expression of DUX4 in the FSHD myoblasts. A previous study reported that 
suppressing wnt signaling activated DUX4 expression [19]. The wnt suppressive effects of KOSR may 
have increased DUX4 expression in this case. In addition, FSHD cells have been shown to be susceptible 
to oxidative stress [29]. KOSR contains antioxidant such as selenium and ascorbate, which have been 
shown to protect stem cells from apoptosis. FSHD myoblasts cultured in KOSR may have been better 
protected from oxidative stress and apoptosis, therefore higher number of DUX4-positive cells 
survived in culture. 
Dexamethasone has been shown to suppress wnt signaling in epithelial and osteoblasts cells [30,31]. 
Whether it suppresses wnt signaling in myoblasts is not clear. In addition to effects on wnt signaling, 
dexamethasone has been shown to increase ROS generation and apoptosis in proliferating human 
rhabdomyosarcoma cells [32]. In this case, dexamethasone may potentially increase DUX4 expression. 
Our data showed lower expression of DUX4 when the FSHD myoblasts were cultured in media with 
dexamethasone. One explanation is that the myoblasts cultured in dexamethasone may die quicker due 
to oxidative stress and cell death signaling induced by dexamethasone, implicating a narrow window 
for DUX4 detection. Since adding dexamethasone is a common practice in cell culture, whether it is 
harmful to the DUX4 expressing cells need to be further investigated.  
Our studies showed that reverse transcriptase enzymes and primers used for cDNA synthesis 
significantly affect the detection of DUX4 in FSHD myoblasts in culture. Superscript III and oligo(dT) 
are the best combination when synthesize cDNA for DUX4 detection. Differences in culture 
conditions including dexamethasone which are often added for improving cell proliferation and 
knockout serum replacement (KOSR) significantly affect the expression of DUX4. The addition of 
KOSR in culture increased DUX4 while dexamethasone reduced DUX4 detection. Understanding the 
molecular mechanisms underlying these observations may help decipher regulation of DUX4 
expression in FSHD myoblasts. 
3. Materials and Methods 
3.1. Human Myoblasts Culture 
Immortalized and primary myoblasts were obtained from the Senator Paul Wellstone Muscular 
Dystrophy Cooperative Research Center at Boston Biomedical Research Institute [33]. The patient 
myoblast cell line was derived from the biceps of a 42 year-old male with mild muscle weakness.  
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The control myoblasts were derived from the patient’s 46 year-old brother without FSHD [33,34]. 
These cells were cultured as previously described [33–35]. Briefly, both the immortalized and  
primary myoblasts were cultured in LHCN medium with or without dexamethasone (140 nM/mL)  
(Sigma-Aldrich, St. Louis, MO, USA) [4:1 DMEM:Medium 199 supplemented with 15% characterized 
FBS (Hyclone, South Logan, UT, USA), 0.02 M HEPES (Sigma-Aldrich), 0.03 mg/mL ZnSO4 (Sigma), 
1.4 mg/mL Vitamin B12 (Sigma-Aldrich), 2.5 ng/mL hepatocyte growth factor (Chemicon 
International, Temecula, CA, USA), 10 ng/mL basic fibroblast growth factor (Millipore, Billerica, MA, 
USA) 0.02 M HEPES, and (Life Technologies)] kat 37 °C, 5% CO2 for 6 days. For testing the effects 
of KOSR, 15% FBS in the LHCN medium were replaced with 15% KOSR (either with or without 
dexamethasone) for 3 days before the cells were collected for RNA isolation. Total RNA was isolated 
using mirVANA kit (Life Technologies). Quadruplicates were performed for all studies. 
To determine the effects of KOSR concentrations on DUX4 expression in differentiating myoblasts, 
immortalized FSHD and unaffected myoblasts were cultured in LHCN medium without dexamethasone 
for 3 days. The LHCN medium was then replaced with differentiation medium. The differentiation 
medium consist of antibiotics/antimycotics 1%, L-glutamine 2 mM, sodium pyruvate 1 mM, HEPES 
0.02 M and 2% HS or different concentrations of KOSR (2%, 10%, 15% and 20%). The myoblasts were 
differentiated for 7 days then harvested for RNA isolation using the mirVANA kit (Life Technologies). 
3.2. The cDNA Synthesis and RT-PCR 
RNA isolation, cDNA synthesis, semi-quantitative RT-PCR were performed as previously 
described [35]. Total RNA was isolated using mirVANA kit (Life Technologies) according to the 
manufacturer’s protocol. Three micrograms of total RNA was treated with DNase I (Promega, 
Madison, WI, USA) digestion by incubating at 37 °C for 30 min to remove genomic DNA 
contamination. The reaction was inactivated by solution provided in the kit (Promega) and heated for 
10 min at 65 °C. The samples were purified using the RNeasy MinElute Cleanup Kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s protocol. Subsequently, the 1 µg of RNA sample was 
reverse transcribed to cDNA using Superscript II and Superscript III (Life Technologies), respectively. 
Briefly, RNA samples were incubated at 65 °C for 5 min with 1 µL dNTPs (10 mM each) (New 
England Biolab, Ipswich, MA, USA) and 1 µL oligo(dT)12–18 (Life Technologies) or 1 µL of random 
hexamers (Life Technologies), respectively. Thereafter, a master mix of 4 µL 5X first strand buffer 
(Life Technologies), 1 µL DTT (Life Technologies), 1 µL RNasin (Promega) and either Superscript II 
or Superscript III (Life Technologies), respectively, were added in each reaction and incubated for  
25 °C for 5 min, 50 °C for 1 h and 70 °C for 15 min. The 1 µL of RNase H (Life Technologies) was 
added to each reactions of cDNA synthesis and incubated for 37 °C for 20 min. 
The cDNA was amplified using GoTaq green master Mix (Promega) using 1 µM of forward and 
reverse primers specific to each gene and 3 µL (60 ng) of cDNA template in a total volume of 20 µL. 
The thermal cycling conditions are 95 °C for 3 min, followed by 40 or 30 cycles of 95 °C for 10 s then 
62 °C for 45 s for cDNA samples synthesized from immortalized and primary myoblasts, respectively. 
The samples were kept at 72 °C for 10 min at the end. Primer sequences used for human DUX4 were 
(forward) 5'-CCCAGGTACCAGCAGACC-3' and (reverse) 5-TCCAGGAGATGTAACTCTAATCCA-
3'. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as internal control and  
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the primers used were (forward) 5'-TTGTCAAGCTCATTTCCTGGTATG-3' and (reverse)  
5'-GTGAGGGTCTCTCTCTTCCTCTTGT-3'. The primer sequences for a second internal  
control, 18S rRNA, were (forward) 5'-ATTGCAATTATTCCCCATGAACG-3' and (reverse)  
5'-CACTAAACCATCCAATCGGTAGTAGC-3'. PCR products were visualized in 2.0% agarose gel 
by electrophoresis. Densitometric analysis of EtBr-stained gel for DUX4 and internal control bands 
was performed using Image J software (NIH, Bethesda, MD, USA).  
Real-time qRT-PCR was performed as previously described [12]. The thermal cycling condition 
was an initial 50 °C for 2 min, 95 °C for 10 min, followed by 40 cycles of amplification with 95 °C for 
15 s then 60 °C for 1 min. Primer sequences used for human MYOD were (forward)  
5'-TGCGCAACGCCATCCGCTATA-3' and (reverse) 5'-GGGGCCGCTGTAGTCCATCATG-3'; 
MYOG (forward) 5'-TGCTCAACCCCAACCAGCGG-3' and (reverse) 5'-GCATTCGCTGGG 
CACCCCT-3. T-test was used (p < 0.05) to determine statistical significance. 
Supplementary Materials 
Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/20/05/8304/s1. 
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